SPY734.25+0.17%QQQ651.16+0.63%BTC/USD75,696.20−0.36%DIA513.35−0.18%GLD374.92−0.15%TLT81.84−0.11%

Premium Services

Nuvectis Pharma Inc

NVCTNASDAQ

Trade with Public

Trade with Public

$17.76

-0.71-3.84%

Last update: Nov 5, 4:00 PM

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

Nuvectis Pharma (NVCT) Stock Price Target 2026

The average analyst price target for Nuvectis Pharma is $27, 52.0% above the current price. Of 5 analysts, 5 rate it Buy. Targets range from $17 to $39. The latest change came on Aug 24, 2026, when Cantor Fitzgerald initiated coverage of Nuvectis Pharma with an Overweight rating.

The Average Analyst Price Target for Nuvectis Pharma is $27.

Price Target Range — 7 Quarters

Analyst Consensus — 5 Analysts

5Buy

Consensus RatingBuy# Analysts5Avg. Consensus PT$27Upside to Avg. PT+52.0%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Nuvectis Pharma Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 24, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$39
Aug 24, 2026	Cantor Fitzgerald	Pete Stavropoulos	Initiate	Overweight	—
Jul 6, 2026	Roth Capital	Jonathan Aschoff	PT Raise	Buy	$20→$33
Jun 22, 2026	HC Wainwright & Co.	Joseph Pantginis	PT Raise	Buy	$13→$39
Jun 12, 2026	HC Wainwright & Co.	Joseph Pantginis	PT Raise	Buy	$10→$13
Aug 4, 2025	HC Wainwright & Co.	Joseph Pantginis	PT Cut	Buy	$15→$10
Apr 30, 2025	HC Wainwright & Co.	Joseph Pantginis	PT Raise	Buy	$11→$15
Apr 2, 2025	Maxim Group	Naz Rahman	Initiate	Buy	$17
Mar 17, 2025	Laidlaw & Co.	Yale Jen	Initiate	Buy	$19
Feb 25, 2025	HC Wainwright & Co.	Joseph Pantginis	PT Cut	Buy	$21→$11
Aug 6, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$21
May 8, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$21

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Nuvectis Pharma, Maintains $39 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Nuvectis Pharma (NASDAQ:NVCT) with a Buy and maintains $39 price target.

Benzinga Newsdesk

This Cal-Maine Foods Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday

Analysts downgraded UiPath, Cal-Maine with several price-target cuts.

Avi Kapoor

This Toast Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Wednesday

Wall Street analysts changed outlook on top companies. Check out complete rating changes, including upgrades/downgrades, on our page.

Avi Kapoor

This PG&E Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. BMO Capital

Avi Kapoor

This Sempra Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Mizuho analyst

Avi Kapoor

This Deere Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Baird analyst

Avi Kapoor